Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does Black Diamond Therapeutics, Inc (BDTX) operate in?
Black Diamond Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Black Diamond Therapeutics, Inc (BDTX) current stock price?
As of the latest data, Black Diamond Therapeutics, Inc stock price is $2.05, with a previous close of $2.02. Black Diamond Therapeutics, Inc gained $0.03 in the last trading session, representing a 1.49% increase.
What is Black Diamond Therapeutics, Inc (BDTX) current market capitalization?
Black Diamond Therapeutics, Inc market cap is approximately 117.47 million.
What is Black Diamond Therapeutics, Inc (BDTX) Earnings Per Share (EPS)?
The trailing EPS is -$0.75, and the forward EPS is -$1.15.
What is Black Diamond Therapeutics, Inc (BDTX) EBITDA?
Black Diamond Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.26 million.
Does Black Diamond Therapeutics, Inc (BDTX) pay dividends?
No. Black Diamond Therapeutics, Inc does not pay a dividend.
What is Black Diamond Therapeutics, Inc (BDTX) beta (volatility) score?
Black Diamond Therapeutics, Inc has a beta of 3.288, indicating very high volatility compared to the market.
